Zhuhai Rundu Pharmaceutical Co.Ltd(002923) ( Zhuhai Rundu Pharmaceutical Co.Ltd(002923) ) disclosed the 2021 annual report on April 19. During the reporting period, the company achieved an operating revenue of 1.19 billion yuan, a year-on-year decrease of 5.01%. Among them, the sales of preparation products achieved an operating revenue of 767 million yuan, a year-on-year increase of 5.72%; The sales of APIs and pharmaceutical intermediates achieved an operating revenue of 421 million yuan, a year-on-year decrease of 19.19%, which was mainly affected by the adjustment of product sales price. The company realized a net profit attributable to shareholders of listed companies of 140 million yuan, with a year-on-year increase of 2.87%; The net profit deducted from non profit was 127 million yuan, an increase of 11.33% year-on-year. The company plans to distribute a cash dividend of 4 yuan (including tax) for every 10 shares to all shareholders and increase 3 shares for every 10 shares to all shareholders with capital reserve.
The annual report shows that during the reporting period, the company's preparation marketing team closely followed the relevant policies such as national centralized procurement and regional alliance, overcome the difficulties of the epidemic, and actively prepared and arranged for market access. Irbesartan hydrochlorothiazide tablets of the company were selected in the centralized drug procurement of Guangdong alliance, and isosorbide mononitrate sustained-release capsules were selected in the centralized drug procurement organized by the fifth batch of countries.
In 2021, the company invested 921396 million yuan in R & D, combining independent R & D and external cooperative development, and all research work was carried out in an orderly manner. In terms of innovative drugs, the noraconitine hydrochloride injection project developed by the company is implementing the supplementary research of phase III clinical research; Carboxyamine triazole (class I new drug) obtained the DMF registration number and completed the registration on-site verification. In the development of generic drugs, the development of APIs and preparations went hand in hand, the Chinese registration and international registration were carried out simultaneously, and a number of R & D achievements were made.
In 2021, the construction of each project unit of Rundu Jingmen Company is progressing smoothly. The civil construction of several workshops has been completed, and some supporting facilities such as the central control room have been put into use. One workshop has been completed and qualified to enter the trial production stage. In 2022, many workshops will be put into use one after another. The construction of Rundu Jingmen Company will become a professional production platform for the company's high-end APIs and intermediates, greatly improve the large-scale and multi-functional production capacity of APIs and intermediates, effectively promote the layout of the company's industrial chain and promote the healthy and stable development of the company.
On the same day, the company simultaneously disclosed the first quarter report of 2022. From January to March, the company realized an operating revenue of 323 million yuan, a slight decrease of 0.43% over the same period, and realized a net profit attributable to shareholders of listed companies of 381241 million yuan, a year-on-year increase of 8.79%.
